Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-407 China Extension: Pembrolizumab + Chemotherapy in Metastatic Squamous NSCLC
NCT03875092Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2017
- Primary completion
- Sep 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pembrolizumab in squamous cell carcinoma of the lung (SCCL) (2 arms), sponsored by Merck & Co. Primary endpoints: Progression-free Survival at 33 months and Overall Survival at 39 months. Started Apr 2017; status: completed.
02
Drugs
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT03875092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03875092.